Oxford Biomedica Transforms With New Deals, R&D Pipeline, And Manufacturing Facilities
CAR-T and TCR-T Program Deal Signed With Juno
The lentivirus gene delivery company, Oxford Biomedica, is to collaborate with Juno Therapeutics on its CAR-T and TCR-T projects, adding to the UK biotech’s transformation into a debt-free company with a growing in-house product pipeline.
You may also be interested in...
Bristol-Myers Squibb is to give away more medicines to uninsured US patients, Cancer Research UK tells of funding hardship, Oxford Biomedica joins a consortium to rapidly develop a vaccine, while a Korean company works on a stem cell therapy.
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
Oxford Biomedica and Microsoft have joined forces to improve the yield and quality of next-generation gene therapy vectors using the cloud and machine learning, the UK gene and cell therapy company's chief business officer tells Scrip.